You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Why VYXEOS for sAML treatment?

A variety of factors are considered when determining whether or not VYXEOS (vix-e-ose) is the right treatment. These factors may include your age, your overall health, and whether you have a confirmed diagnosis of secondary acute myeloid leukemia (sAML), specifically therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Only a healthcare provider can decide if VYXEOS is the best course of treatment.

How VYXEOS may help

VYXEOS provides the chance to live longer and spend less time connected to an intravenous (IV) infusion line during treatment compared to the standard chemotherapy treatment

In a clinical trial including older adult patients with t-AML or AML-MRC in which patients received either VYXEOS or the standard AML chemotherapy treatment:

Median survival time of secondary AML patients

Estimated survival at 1 year for secondary AML patients

Secondary AML patients who achieved complete remissionb

Secondary AML patients who received a hematopoietic stem cell transplant (HSCT)

VYXEOS may cause serious side effects, including:

Temp icon

Fever, signs of infection, or bruising or bleeding which can result in serious infection and/or bleeding and possibly lead to death. You should tell your doctor about new onset fever or symptoms of infection or if you notice signs of bruising or bleeding.

Heart icon

Signs of heart failure such as shortness of breath or trouble breathing; swelling or fluid retention, especially in the feet, ankles, or legs; or unusual tiredness.

Caution icon

The most common side effects reported by patients receiving VYXEOS are bleeding events, fever, rash, swelling, nausea, sores in the mouth or throat, diarrhea, constipation, muscle pain, tiredness, stomach pain, difficulty breathing, headache, cough, decreased appetite, irregular heartbeat, pneumonia, blood infection, chills, sleep disorders, and vomiting.

These are not all of the possible side effects of VYXEOS. Be sure to speak to your healthcare team about any side effects you have.

Please see full Prescribing Information, including BOXED Warning, and discuss with your doctor.


VYXEOS is an intravenous (IV) chemotherapy used for the treatment of certain types of newly-diagnosed acute myeloid leukemia (AML) in adults and pediatric patients 1 year and older, including patients whose AML is related to previously received chemotherapy or radiation therapy (also called therapy-related AML, t-AML) and AML in patients who previously had certain types of blood disorders (also called AML with myelodysplasia-related changes, AML-MRC).


Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.